Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 732 in Thyroid Eye Disease (HAZEL 401)
NCT07438405Phase 2Recruiting
- Sponsor
- Amgen
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of AMG 732 in thyroid eye disease (TED), sponsored by Amgen. Started May 2026; status: recruiting.
02
Drugs
AMG 732
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07438405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438405.